New evidence shows SARS-CoV-2 mutations are not more transmissible
In direct contrast to previous research, researchers found that SARS-CoV-2 mutations are not tied to increased transmissibility in humans. The findings, published in Nature Communications on November 25 suggest that mutations such as D614G, while common, are neutral to viral evolution.  Discuss
EC secures 80M doses of Moderna COVID-19 vaccine
Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.
Altimmune submits IND for single dose intranasal COVID-19 vaccine
Altimmune has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to begin a phase I clinical trial of its single-dose intranasal COVID-19 vaccine, AdCOVID.
Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity efforts, including COVID-19 vaccine infrastructure.
Covaxx to deliver over 140M vaccine doses to emerging countries
Covaxx, a subsidiary of United Biomedical, has received purchase commitments of more than 140 million doses of its UB-612 COVID-19 vaccine, totaling over $2.8 billion. The vaccine will be delivered to multiple countries including Brazil, Ecuador, and Peru.
Superspreader events drive global SARS-CoV-2 transmission
So-called "superspreader events" have been a major contributor to widespread transmission of the SARS-CoV-2 virus, according to a new analysis of outbreaks in Austria. Researchers used deep viral genome sequencing to trace the evolution of the pandemic in the country and how the virus spread beyond its borders, according to a study published in Science Translational Medicine on November 23.  Discuss
ReiThera touts phase I COVID-19 vaccine results
ReiThera is highlighting positive phase I clinical trial results for its COVID-19 vaccine candidate, GRAd-COV2.
Capricor begins phase II trial of COVID-19 cell therapy
Capricor Therapeutics has begun a phase II trial of its CAP-1002 cell therapy for patients with severe COVID-19 disease.
City of Hope initiates SARS-CoV-2 vaccine phase I trial
The City of Hope has begun a phase I clinical trial of COH04S1, which is its investigational SARS-CoV-2 vaccine, in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
Older adults likely to get COVID-19 vaccine, but some say they want to wait
A new poll of older adults indicates that that there is some hesitancy among the group when asked if they would get an effective COVID-19 vaccine.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter